Market by Product Type, Therapeutic Application, and End-user | Forecast 2023-2028
Triton Market Research’s
report predicts that the market for botulinum toxin type A in Japan is set to
register a CAGR of 11.02% over the
forecast period 2023-2028. It is
anticipated to obtain revenue worth $XX million by 2028.
Botulinum toxin type A
is off-label for various conditions such as neurogenic thoracic outlet
syndrome, myofascial pain, post-herpetic neuralgia, epicondylitis, post-stroke
pain, trigeminal neuralgia, diabetic neuropathy, neuropathic pain, spinal cord
injury, and bladder pain.
The pure botulinum
toxin type A, known as miracle poison, prevents acetylcholine release in
treating dystonia, persistent sialorrhea, and muscle stiffness. Injection of botulinum
toxin into muscles causes neuromuscular blockade and relaxation, suitable for
addressing muscle hyperactivity disorders including spasticity types,
hemifacial spasm, infantile cerebral palsy, tremor, tics, as well as GI tract
and bladder motility issues like strabismus, detrusor overactivity, cervical
dystonia, post-stroke spasticity, and blepharospasm.
The popular preparation
is available in commercially viable versions in Japan: Botox® (Allergan
Pharmaceuticals), Xeomin® (Merz Pharmaceuticals), and Dysport® (Ipsen
Pharmaceuticals). In Japan, the government organization- Pharmaceuticals and
Medical Devices Agency (PMDA) reviews drugs & medical devices, oversees
post-market safety, and addresses adverse health effects. The PMDA operates
under the Ministry of Health, Labor and Welfare (MHLW).
With rising awareness regarding the medical benefits of botulinum
toxin, several global companies have entered the Japanese market. For instance,
the Japanese Ministry of Health, Labour, and Welfare (MHLW) authorized Merz
Pharmaceuticals and Teijin Pharma Limited to market Xeomin®
(incobotulinumtoxinA) for intramuscular injection in doses of 50, 100, or 200
units for the management of upper limb spasticity in June 2020. These factors
have encouraged many market players to enter the market, which has increased
competitiveness.
Triton Market
Research’s report provides in-depth insight into the Japan botulinum toxin type
A market, along with segmentation analysis. The detailed analysis of the market
includes PEST analysis, current market trends, regulatory framework, and
insurance system & reimbursements. The
segmentation analysis includes market by product type, therapeutic application,
and end-user.
The
key players for the botulinum toxin type A market are AbbVie Inc, Merz Pharma,
Ipsen Pharma, Hugel Inc, and Medytox Inc.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. JAPAN
BOTULINUM TOXIN TYPE A MARKET – SUMMARY
1.1. MARKET
SIZE & FORECAST
1.2. COUNTRY
ANALYSIS
1.3. MARKET
DRIVING ASPECTS
1.3.1. FAVORABLE
PARTNERSHIPS AID IN MARKET GROWTH
1.3.2. SURGE
IN SPASTIC DISORDERS
1.4. MARKET
RESTRAINING ASPECT
1.4.1. POST-ADMINISTRATION
COMPLICATIONS
2. JAPAN
BOTULINUM TOXIN TYPE A MARKET OUTLOOK
2.1. PEST
ANALYSIS
2.2. CURRENT
MARKET TRENDS
2.3. KEY
MARKET STRATEGIES
2.3.1. COLLABORATIONS
2.3.2. PRODUCT
LAUNCHES AND DEVELOPMENTS
2.3.3. ACQUISITIONS
2.4. POTENTIAL
FOR NEW ENTRANTS IN JAPAN BOTULINUM TYPE A MARKET
2.5. MARKET
ATTRACTIVENESS INDEX
2.6. REGULATORY
FRAMEWORK
2.7. INSURANCE
SYSTEM AND REIMBURSEMENTS
2.7.1. HEALTHCARE
& INSURANCE SYSTEM
2.7.2. REIMBURSEMENT
FOR THERAPEUTIC BOTOX TREATMENT
3. JAPAN
BOTULINUM TOXIN TYPE A MARKET OUTLOOK - BY PRODUCT TYPE
3.1. ABOBOTULINUMTOXIN
TYPE A
3.2. INCOBOTULINUMTOXIN
TYPE A
3.3. ONABOTULINUMTOXIN
TYPE A
4. JAPAN
BOTULINUM TOXIN TYPE A INDUSTRY OUTLOOK - BY THERAPEUTIC APPLICATION
4.1. CHRONIC
MIGRAINE
4.2. SPASTIC
DISORDERS
4.3. CERVICAL
DYSTONIA
4.4. DETRUSOR
OVERACTIVITY
4.5. OTHER
THERAPEUTIC APPLICATIONS
5. JAPAN
BOTULINUM TOXIN TYPE A MARKET OUTLOOK - BY END-USER
5.1. HOSPITALS
AND CLINICS
5.2. OTHER
END-USERS
6. COMPETITIVE
LANDSCAPE
6.1. ABBVIE
INC
6.2. HUGEL
INC
6.3. IPSEN
PHARMA
6.4. MERZ
PHARMA
6.5. MEDYTOX
INC
7. RESEARCH
METHODOLOGY & SCOPE
7.1. RESEARCH
SCOPE & DELIVERABLES
7.2. SOURCES
OF DATA
7.3. RESEARCH
METHODOLOGY
TABLE 1: REGULATORY FRAMEWORK
FOR JAPAN BOTULINUM TOXIN TYPE A MARKET
TABLE 2: JAPAN BOTULINUM TOXIN
TYPE A MARKET, BY PRODUCT TYPE, 2023-2028 (IN $ MILLION)
TABLE 3: JAPAN BOTULINUM TOXIN
TYPE A MARKET, BY THERAPEUTIC APPLICATION, 2023-2028 (IN $ MILLION)
TABLE 4: JAPAN BOTULINUM TOXIN
TYPE A MARKET, BY END-USER, 2023-2028 (IN $ MILLION)
TABLE 5: LIST OF BOTULINUM
TOXIN TYPE A MARKET COLLABORATIONS
TABLE 6: LIST OF BOTULINUM
TOXIN TYPE A MARKET PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 7: LIST OF BOTULINUM
TOXIN TYPE A MARKET ACQUISITIONS
FIGURE 1: MARKET
ATTRACTIVENESS INDEX
FIGURE 2: OUTLINE OF PMDA'S
PROCESS FOR PRODUCT APPROVAL IN JAPAN
FIGURE 3: SOCIAL MEDICAL
INSURANCE SCHEME IN JAPAN
FIGURE 4: JAPAN BOTULINUM
TOXIN TYPE A MARKET, BY PRODUCT TYPE, 2022 & 2028 (IN %)
FIGURE 5: JAPAN BOTULINUM
TOXIN TYPE A MARKET, BY ABOBOTULINUMTOXIN TYPE A, 2023-2028 (IN $ MILLION)
FIGURE 6: JAPAN BOTULINUM
TOXIN TYPE A MARKET, BY INCOBOTULINUMTOXIN TYPE A, 2023-2028 (IN $ MILLION)
FIGURE 7: JAPAN BOTULINUM
TOXIN TYPE A MARKET, BY ONABOTULINUMTOXIN TYPE A, 2023-2028 (IN $ MILLION)
FIGURE 8: JAPAN BOTULINUM
TOXIN TYPE A MARKET, BY THERAPEUTIC APPLICATION, 2022 & 2030 (IN %)
FIGURE 9: JAPAN BOTULINUM
TOXIN TYPE A MARKET, BY CHRONIC MIGRAINE, 2023-2028 (IN $ MILLION)
FIGURE 10: JAPAN BOTULINUM
TOXIN TYPE A MARKET, BY SPASTIC DISORDERS, 2023-2028 (IN $ MILLION)
FIGURE 11: JAPAN BOTULINUM
TOXIN TYPE A MARKET, BY CERVICAL DYSTONIA, 2023-2028 (IN $ MILLION)
FIGURE 12: JAPAN BOTULINUM
TOXIN TYPE A MARKET, BY DETRUSOR OVERACTIVITY, 2023-2028 (IN $ MILLION)
FIGURE 13: JAPAN BOTULINUM
TOXIN TYPE A MARKET, BY OTHER THERAPEUTIC APPLICATIONS, 2023-2028 (IN $ MILLION)
FIGURE 14: JAPAN BOTULINUM
TOXIN TYPE A MARKET, BY END-USER, 2022 & 2030 (IN %)
FIGURE 15: JAPAN BOTULINUM
TOXIN TYPE A MARKET, BY HOSPITALS AND CLINICS, 2023-2028 (IN $ MILLION)
FIGURE 16: JAPAN BOTULINUM
TOXIN TYPE A MARKET, BY OTHER END-USERS, 2023-2028 (IN $ MILLION)